Pharmacological management of chemotherapy-induced nausea and vomiting

Drugs

Volumn 69, Issue 5, 2009, Pages 515-533

  Navari, Rudolph M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APREPITANT; BORTEZOMIB; CANNABINOID; CARBOPLATIN; CARMUSTINE; CASOPITANT; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; ETOPOSIDE; FLUOROURACIL; GABAPENTIN; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; OLANZAPINE; OXALIPLATIN; PALONOSETRON; PLACEBO; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE;

ALOPECIA; ASTHENIA; BINDING AFFINITY; BONE MARROW TRANSPLANTATION; BREAST CANCER; CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DRUG USE; FATIGUE; FOOD AND DRUG ADMINISTRATION; HICCUP; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; UNITED STATES;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NAUSEA; QUALITY OF LIFE; RISK FACTORS; VOMITING;

EID: 64949104350     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969050-00002     Document Type: Review

References (96)

1. NCCN Clinical Practice Guidelines in Oncology; v0.2.2006: Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. Available from URL: http://www. nccn.org/professionals/physician-gls/PDF/antiemesis.pdf. [Accessed 2006 Nov 22]
2. Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007; 15 (5): 497-503
3. Bloechl-Daum B, Deuson RR, Mavros P, et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006; 24: 4472-8
4. 3 antagonist and a corticosteroid in patients receiving anthracy-clines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 2005; 104: 864-8
5. Schwartzberg L. Chemotherapy-induced nausea and vomiting: state of the art in 2006. J Support Oncol 2006; 4 (2) Suppl. 1: 3-8
6. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 2005; 13: 80-4
7. Guyton AC. Physiology of gastrointestinal disorders. In: Guyton AC, Hall JE, editors. Textbook of medical physiology. Philadelphia (PA): Elsevier Saunders, 2006
8. Baker PD, Morzorati SL, Ellett ML. The pathophysiology of chemotherapy-induced nausea and vomiting. Gastroenterol Nurs 2005; 28: 469-80
9. Koga T, Fukuda H. Neurons in the nucleus of the solitary tract mediating inputs from vagal afferents and the area postrema in the pattern generator in the emetic act in dogs. Neurosci Res 1992; 14: 366-79
10. Yates BJ, Grelot L, Kennan IA, et al. Organization of the vestibular inputs to nucleus tractus solitarius and adjacent structures in cat brain stem. Am J Physiol 1994; 267: R974-83
11. Navari RM. Review of updated antiemetic guidelines for chemotherapy-induced nausea and vomiting. Commun Oncol 2007; 4 (1 Suppl.): 3-11S
12. Roila F, Hesketh PJ, Herrstedt J. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-8
13. Kris MG, Hesketh PJ, Somerfíeld MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-47
14. Hesketh PJ, Navari RM, Grote T, et al. Double blind randomized comparison of the antiemetic efficacy of intravenous dolasetron and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. J Clin Oncol 1996; 14: 2242-9
15. Navari RM, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995; 13: 1242-8
16. Navari RM, Kaplan HG, Gralla RJ, et al. Efficacy and safety of granisetron, a selective, 5-hydroxytryptamine receptor antagonist, for the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol 1994; 12: 2204-10
17. Perez EA. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995; 13: 1036-43
18. 3 receptors. London: Academic Press, 1992: 207-55
19. Roila F, Warr D, Clark-Snow R, et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005; 13 (2): 104-8
20. Latreille J, Pater J, Johnston D, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 1998; 16: 1174-8
21. Navari RM, Madajcwicz S, Anderson N, et al. Oral on-dansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13:2408-16
22. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000; 342: 1554-9
23. Geling O, Eichler H. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24. hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005; 23: 1289-94
24. 3 receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 2005; 6: 765-72
25. 3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 1994; 33: 1607-8
26. 3 receptor antagonists and antiemesis. In: King FD, Jons BJ, Sanger GJ, editors. 5-Hydroxy-tryptamine-3 receptor antagonists. Boca Raton (FL): CRC Press, 1994:255-317
27. Hesketh PJ. New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer 2004; 12: 550-4
28. Mantovani G, Maccio A, Aslexandro B, et al. Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer; a randomized controlled trial. Cancer 1996; 77: 941-8
29. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol 2003; 1: 89-103
30. Simpson K, Spencer CM, McClellan KJ. Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000; 59: 1297-315
31. Kimura E, Niimi E, Watanabe A, et al. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 1996; 23: 477-81
32. Taguchi T, Tsukamoto F, Watanabe T, et al. Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho 1999; 26: 1163-70
33. 3 receptor anta-gonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000; 18: 163-73
34. Perez EA, Navari RM, Kaplan HG, et al. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer 1997; 5: 31-7
35. Navari RM, Koeller JM. Electrocardiographic and cardio-vascular effects of the 5-hydroxytryptamine-3 receptor antagonists. Ann Pharmacother 2003; 37: 1276-86
36. Hickok JT, Roscoe JA, Morrow GR, et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5 hydroxytryptamine-3 anti-emetics. Cancer 2003; 97: 2880-6
37. 3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-82
38. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-7
39. Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-9
40. 3 receptor antagonist [abstract]. Proc Am Soc Clin Oncol 2003 May 31-Jun 3; Chicago (IL), 3041
41. Kris MG. Why do we need another antiemetic? J Clin Oncol 2003;21:4077-80
42. Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000; 60: 533-46
43. Fasth KJ, Bergstrom M, Kilpatrick G Brain uptake and receptor binding of two C11 labeled selective high affinity NK-1 antagonists, GR 203040 and GR 205171. J Labeled Comp Radiopharm 1997; 40: 665-7
44. Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK-1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996; 35: 1121-9
45. Minami M, Endo T, Kikuchi K, et al. Antiemetic effects of sendide, a peptide tachykinin NK-1 receptor antagonist, in the ferret. Eur J Pharmacol 1998; 363: 49-55
46. 3 receptors. Eur J Pharmacol 2001; 428: 215-20
47. Tattersall FD, Rycroft W, Cumberbatch M, et al. The novel NK-1 receptor antagonist MK-869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 2000; 39: 652-63
48. Kris MG, Radford JE, Pizzo BA, et al. Use of a NK-1 receptor antagonist to prevent delayed emesis after cisplatin [letter]. J Natl Cancer Inst 1997; 89: 817-8
49. Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin-1 receptor antagonist CJ-11, 974 in the control of cisplatin-induced emesis. J Clin Oncol 1999; 17: 338-43
50. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokin-1 receptor antagonist. N Engl J Med 1999; 340: 190-5
51. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer 2001; 37: 835-42
52. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19: 1759-67
53. Van Belle S, Liechinitser M, Navari RM, et al. Prevention of cisplatin- induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002; 94: 3032-41
54. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK-1 antagonist Aprepitant for chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290-300
55. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin: the Aprepitant protocol 052 study group. J Clin Oncol 2003; 21: 4112-9
56. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 3090-8
57. De Wit R, Herrstedt J, Rapoport BL, et al. Addition of the oral NK-1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003; 21: 4105-11
58. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006; 17 (6): 1000-6
59. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822-30
60. Navari RM. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and antinausea activities. Curr Opin Investig Drugs 2008; 9: 774-85
61. De Wit R, Herrstedt J, Rapoport B, et al. The oral NK-1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials. Eur J Cancer 2004; 40: 403-10
62. Navari RM. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2004; 4 (5): 715-24
63. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 777-94
64. Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 2007; 16: 1977-85
65. Lasseter KC, Gambale J, Jin B, et al. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. J Clin Pharmacol 2007; 47: 834-40
66. Arpornwirat W. Multicenter randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK1 RA) casopitant mesylate for chemotherapy-induced nausea/ vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC) [abstract]. Proc Am Soc Clin Oncol 2006 Jun 2-6; Atlanta (GA), 8512
67. Rolski J. Randomized phase II trial of the neurokinin-1 receptor antagonist (NK1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) [abstract]. Proc Am Soc Clin Oncol 2006 Jun 2-6; Atlanta (GA), 8513
68. Grunberg SM, Aziz Z, Shaharyar A, et al. Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC) [abstract]. Proc Am Soc Clin Oncol 2008 May30-Jun 3; Chicago (IL), 9540
69. Strausz J, Rolski J, Aziz Z, et al. Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC) [abstract]. Proc Am Soc Clin Oncol 2008 May 30-Jun 3; Chicago (IL), 20585
70. GlaxoSmithKline. Post-operative nausea and vomiting study in female patients [ClinicalTrials.gov identifier NCT00274690]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL http://www.clinical trials.gov [Accessed 2008 May 13]
71. GlaxoSmithKline. Study of iv casopitant for the prevention of chemotherapy-induced nausea and vomiting [Clinical Trials.gov identifier NCT00601172]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 May 13]
72. Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12: 596-600
73. The Italian Group for Antiemetic Research. Dexa-methasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5
74. Latreille J, Stewart D, Laberge F, et al. Dexamethasone improves the efficacy of granisetron in the first 24h following high-dose cisplatin chemotherapy. Support Care Cancer 1995; 3: 307-12
75. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexa-methasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000; 18: 3409-22
76. The Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998; 16: 2937-42
77. The Italian Group for Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carbo-platin, or cyclophosphamide [published erratum appears in J Clin Oncol 2004; 22: 2038]. J Clin Oncol 2004; 22: 725-9
78. Bymaster FP, Calligaro D, Falcone J, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96
79. 6 receptors by olanzapine. Eur J Pharmacol 2001; 430: 341-9
80. Allison DB, Casey DE. Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry 2001; 62: 22-31
81. Hale AS. Olanzapine. Br J Hosp Med 1997; 58: 443-5
82. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438-43
83. Passik SD, Navari RM, Loehrer PJ, et al. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest 2004; 22: 383-8
84. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 2005; 13: 529-341634-46
85. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory Cancer 2000; 89: 1634-46
86. Navari RM, Einhorn LH, Loehrer PJ, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 2007; 15: 1285-91
87. Guttuso T, Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 2003; 361: 1703-5
88. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem canna-binoid CB2 receptors. Science 2005; 310: 329-32
89. Martin BR, Wiley JL. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2004; 2: 305-16
90. Slatin MD. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 2007; 5 (3 Suppl.): 1-9S
91. Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002; 10: 517-8
92. Navari RM. Prevention of emesis from multiple-day chemotherapy regimens. J Natl Compr Canc Netw 2007; 5: 51-9
93. Einhorn LH, Brames ML, Dreicer R, et al. Palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007; 15: 1293-300
94. Fabi A, Ciccarese M, Metro G, et al. Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. Support Care Cancer 2008; 16: 1375-80
95. Grunberg SM, Deuson R, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer 2004; 100: 2261-8
96. Fabi A, Barduagni M, Lauro S, et al. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 2003; 11: 156-61